Orum Therapeutics, Inc. announced the appointment of Maria Koehler, M.D., Ph.D., and Geoff Meyerson to its Board of Directors, following approval at the Company?s Annual General Meeting, which took place March 27, 2026. Orum is advancing GSPT1-directed TPD²® programs and developing novel degrader payloads to expand the potential of DACs in oncology and beyond. Dr. Koehler is an oncology biotech executive, hematologist/oncologist, and board director with more than 20 years of experience across clinical development, regulatory strategy, translational oncology, medical affairs, and biomarker-driven drug development.
Most recently, she served as Venture Partner with Omega Funds and Senior Advisor to Viking Global, and until March 2025 was Chief Medical Officer of Repare Therapeutics, where she led clinical, regulatory strategy, and operations. She previously served as Chief Medical Officer of Bicycle Therapeutics and held senior oncology development roles at Pfizer, GSK, and AstraZeneca, including leadership of IBRANCE® (palbociclib) development at Pfizer. Dr. Koehler has played a prominent role in early oncology development and biomarker strategy, has authored more than 170 peer-reviewed publications and chapters, and has served on multiple public and private company boards, including Abdera Therapeutics, REMIX Therapeutics, Ikena, Silverback, and Celyad.
Mr. Meyerson is a life science entrepreneur, strategic advisor, and transaction leader with experience spanning biotech investment banking, business development, venture capital, and company creation. He is Co-founder and CEO of Locust Walk, and Co-founder of Franklin Life Science, Venning Life Sciences, and BioBreak. He brings a broad perspective shaped by work across strategic transactions and company-building in the life sciences, with expertise in business development, M&A negotiations and deal structuring, venture capital investing, and growth strategy.
